Interestingly, in lithium-treated BD patients, GFAP and Olig1 expression levels were comparable to those in the control group, suggesting that lithium’s effect on mRNA glial markers may result from a reduction in the inflammatory response in the central nervous system (Ferensztajn-Rochowiak et al. 2016). This evidence concerns the gene GFAP and Behcet disease.